Vaccine trial for early Parkinson’s meets primary objectives
UB-312, an experimental vaccine by Vaxxinity, appeared safe and well tolerated and was able to produce an immune response against…
Articles by Margarida Maia, PhD
Axial awarded second MJFF grant for gut-targeting therapy
Axial Therapeutics will use a new research grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF)…
Less active brain waves may signal cognitive decline in Parkinson’s
People with Parkinson’s disease who are experiencing cognitive decline may show weaker low-frequency brain waves on an electroencephalogram (EEG),…
MJFF grant will help Icometrix ID brain MRI biomarkers in Parkinson’s
A grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) will allow Icometrix — a company focused…
1st patient dosed in 201 trial of IkT-148009 for Parkinson’s
Inhibikase Therapeutics, which is recruiting up to 120 untreated Parkinson’s disease patients across the U.S. to test its…
Acorda, Chance enter agreement to sell Inbrija in China
Acorda Therapeutics has entered into an agreement with Chance Pharmaceuticals for Inbrija (levodopa inhalation powder), a medication…
Inhibikase takes steps ahead of ‘201’ study of IkT-148009 in Parkinson’s
A once-daily 200 mg dose of IkT-148009, Inhibikase Therapeutics‘ investigational therapy for Parkinson’s disease, reached steady levels in…
FDA needs additional information before approval of ABBV-951
The U.S. Food and Drug Administration (FDA) has requested more information about the specialized pump used to administer ABBV-951…
IMAC, Brain Scientific merger to offer range of neurological care
IMAC Holdings and Brain Scientific have agreed to merge to offer solutions that cover the spectrum of care…
Early NfL blood levels differ in idiopathic and LRRK2 Parkinson’s
People with idiopathic Parkinson’s disease have significantly higher blood levels of neurofilament light chain (NfL) — a biomarker of nerve…